Alessandro Agnarelli
London, ENG EC1M6BQ, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
A Regulatory Element in the Intrinsically Disordered C-Terminal Region of LMTK3 Modulates Its Kinase Domain Interactions and Breast Cancer Phenotypes.
Journal: Cells
Published: June 25, 2026
Loss of CHTF18-RFC2/5 leads to replicative gaps and sensitivity to PARP inhibitors.
Journal: NAR cancer
Published: December 04, 2025
The genetic and biochemical basis of human leading strand synthesis.
Journal: Nature communications
Published: April 22, 2025
'Where is my gap': mechanisms underpinning PARP inhibitor sensitivity in cancer.
Journal: Biochemical Society transactions
Published: December 08, 2024
Loss of POLE3-POLE4 unleashes replicative gap accumulation upon treatment with PARP inhibitors.
Journal: Cell reports
Published: December 01, 2023
The Inhibitory Properties of a Novel, Selective LMTK3 Kinase Inhibitor.
Journal: International journal of molecular sciences
Published: September 22, 2022
Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4-MYC oncogenic axis in multiple myeloma.
Journal: Hematological oncology
Published: November 22, 2021
Phosphorus and sulfur SAD phasing of the nucleic acid-bound DNA-binding domain of interferon regulatory factor 4.
Journal: Acta crystallographica. Section F, Structural biology communications
Published: May 01, 2021
IRF4 in multiple myeloma-Biology, disease and therapeutic target.
Journal: Leukemia research
Published: May 22, 2018
Showing 1-10 of 10
Last Updated: 09/26/2026